Board of directors
Thierry Sulpice, Ph.D
Dr. Thierry Sulpice has served as the Chief Scientific Officer of Physiogenex since September 2004. Prior to joining Physiogenex he was head of the in vivo pharmacology team working on new cardiometabolic targets at Sanofi-Aventis.
During his 9-year tenure at Sanofi-Aventis, Thierry was in charge of drug discovery optimization and preclinical development for projects targeting the cardiometabolic syndrome. He was particularly involved in the cannabinoid CB1 receptor program. He managed many animal studies which aimed to determine the potential efficacy of new drug targets. He developed several in vivo technologies and new animal models which directly reproduced metabolic disorders and heart diseases.
His expertise also covers the physiopathology and pharmacology of type 2 diabetes, dyslipidemia, vascular/heart diseases, liver and kidneys disorders. Thierry holds a PhD in Physiology and Pharmacology from the University of Grenoble, France. Since 1990 he has been actively engaged in basic research on cardiovascular physiopathology and spent one tear working on the physiopathology of the diabetic heart at Orsay University, France.
In addition, Dr. Thierry Sulpice is the CEO and founder of Betagenex, a Canadian preclinical CRO specializing in the role of pancreatic beta-cells in metabolic disorders. He is also the founder and CEO/CSO of Cardiomedex, a preclinical and clinical CRO dedicated to cardiovascular disorders, onco-cardiology and neurocardiology
François Briand, Ph.D
Dr. Briand has served as an expert in metabolic diseases since October 2007. He has worked extensively on the development of novel in vivo assays and animal models of obesity/type 2 diabetes and related co-morbidities, all presented in international meetings and published in numerous publications.
Dr. Briand received the ASBMB Journal of Lipid Research Junior Investigator Award in 2016, as well as the Berman-Zech Award in 2018, for his research work on preclinical evaluation of drugs targeting type 2 diabetes, dyslipidemia, diabetic nephropathy and NASH.
In 2006, he worked in the laboratory of Pr. Daniel J Rader in Philadelphia, USA. In collaboration with pharmaceutical companies, his work focused on novel drugs affecting lipoprotein metabolism and reverse cholesterol transport in various mouse models.
In 2006, Dr. Briand earned his Ph.D in Nutrition and Metabolism from the University of Nantes, France. It dealt with the development of a canine model of obesity and insulin resistance, for evaluating drugs targeting type 2 diabetes and diabetic dyslipidemia.